key: cord-0747365-agq0wvmy authors: Barkas, Fotios; Anastasiou, Georgia; Milionis, Haralampos; Liberopoulos, Evangelos title: Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated meta-analysis of cardiovascular outcome trials date: 2021-06-06 journal: Diabetol Int DOI: 10.1007/s13340-021-00515-4 sha: be26043687f9ab7b7b836637f819d34983f652f7 doc_id: 747365 cord_uid: agq0wvmy The present meta-analysis included 8 cardiovascular outcome trials with 57,185 patients at high cardiometabolic risk. In comparison with placebo, treatment with sodium-glucose cotransporter inhibitors was associated with a significantly lower risk of pneumonia (RR 0.85, 95% CI 0.76–0.95, p = 0.004; I(2) = 0, p = 0.48). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13340-021-00515-4. Sodium-glucose cotransporter inhibitors (SGLTi) have been associated with impressive cardio-nephro-metabolic benefits in patients with and without diabetes [1] . Although they have been linked with increased incidence of lower genital tract infections, a meta-analysis has recently demonstrated a possible protective effect against incident pneumonia [2] . The latter might be of great interest during the current pandemic of coronavirus disease 2019 . In this context, we performed an updated meta-analysis of cardiovascular outcome trials (CVOTs) investigating the association of SGLTi with the risk of incident pneumonia. The present meta-analysis was based on PRISMA guidelines. Double-blind placebo controlled randomized trials (RCTs) were included in the present meta-analysis if they: (a) represented CVOTs, (b) compared any SGLTi with placebo and (c) included pneumonia in their reported adverse events. Adverse events reported as 'pneumonia' were the outcome of interest. Relevant trials were identified by searching MEDLINE, EMBASE and CENTRAL databases up to 07 Mar 2021 using the following terms: 'cardiovascular', 'sodium-glucose cotransporter inhibitor', 'canagliflozin', 'dapagliflozin', 'empagliflozin', 'ertugliflozin' and 'sotagliflozin'. Two review authors (FB and GA) independently extracted data using a pre-designed data extraction form that contained publication details, study population, randomization, allocation concealment, details of blinding measures, description of interventions and results. Any differences between them were resolved by consulting the other review authors (HM, EL). Bias risk assessment was based on the revised Cochrane riskof-bias tool for randomized trials (RoB 2). We estimated treatment effect using risk ratio (RR) and 95% confidence intervals (CI). Analyses were performed with Revman 5.1. RCTs not reporting the outcome of interest have not been included in this analysis. Heterogeneity between trial results was tested using a standard chi-squared test; p < 0.1 was considered statistically significant. I 2 statistic was used as a measure of heterogeneity. In case of significant heterogeneity (I 2 ≥ 50%), a random-effects model was used. The pooled analysis showed that SGLTi were associated with a significantly reduced risk of pneumonia in comparison with placebo (RR 0.85, 95% CI 0.76-0.95, p = 0.004; I 2 = 0, p = 0.48) (Fig. 1) . Low bias risk was noted within the included studies ( Supplementary Fig. 2 ). The present meta-analysis shows that treatment with SGLTi is associated with a lower incidence of pneumonia in patients at high cardiometabolic risk compared with placebo. A recent meta-analysis of 6 CVOTs with 47,728 participants assigned to treatment with either SGLT2i or placebo demonstrated that there was no difference in the risk of upper respiratory tract infection (RR 0.95, 95% CI 0.48-1.88, I 2 = 0%), lower respiratory tract infection (RR 0.66, 95% CI 0.39-1.13, I 2 = 0%), viral infection (RR 1.15, 95% CI 0.49-2.71, I 2 = 0%) and influenza (RR 1.27, 95% CI 0.70-2.32, I 2 = 0%) [2] . However, the pooled analysis of 5 RCTs (n = 43,430) showed that SGLT2i were associated with decreased risk of pneumonia (RR 0.85, 95% CI 0.75-0.97, I 2 = 0%) [2] . After incorporating the results of VERTIS-CV, DAPA-CKD and SOLOIST, our metaanalysis is the largest (n = 57,185) and most updated to include all available CVOTs reporting on the risk of pneumonia as an adverse event. Possible pathophysiological explanations that might account for the observed reduction in the risk of pneumonia include activation of M2 macrophages, inhibition of lipid raft formation, increased production of ketone bodies, prevention of cytosolic pH reduction and induced shift of energy metabolism towards an increased reliance on lipid oxidation [11] [12] [13] . The reasons for the differential association of SGLT2i with the risk of pneumonia versus upper or lower respiratory infection are unknown [2] . Considering the inflammatory pathways involved in the pathophysiology of pneumonia, the anti-inflammatory properties of SGLT2i may be more relevant [14] . Furthermore, pneumonia is a more objective endpoint since its diagnosis is established with imaging criteria. Although almost all included studies were completed before the onset of the current pandemic, SGLTi treatment merits a role in the COVID-19 era [15] . A propensity-score-matched cohort study (n = 24,865) showed no increased risk of COVID-19 amongst patients treated with SGLT2i compared with dipeptidyl-peptidase 4 inhibitors (adjusted hazard ratio: 0.92, 95% CI 0.66-1.29) [16] . Furthermore, background SGLTi treatment in hospitalized diabetic patients with COVID-19 (n = 2666) has been associated with lower risk of in-hospital mortality (19.4 vs 39.1%, p = 0.003) as compared with other glucose-lowering drugs [17] . A similar beneficial effect of SGLT2i on the mortality risk in patients with diabetes and COVID-19 (hazard ratio: 0.82, 95% CI 0.74-0.91) has been confirmed by a larger observational cohort (n = 2,851,465). [18] . The fact that pneumonia was not the primary outcome of the included studies and was not adjudicated should be acknowledged as a limitation of the present meta-analysis. On the other hand, this is the largest and most updated one to evaluate the association of SGLTi treatment with the risk of pneumonia. The present meta-analysis confirms that treatment with SGLTi is associated with a lower risk of pneumonia compared with placebo in patients at high cardiometabolic risk. In this context, ongoing RCTs (DARE-19 and TACTIC-E) will elucidate the efficacy and safety of SGLTi on the progression, complications and mortality associated with COVID-19 [11, 19] . Considering their cardiovascular benefit, SGLTi should not be interrupted during current pandemic. Nevertheless, they should be cautiously used in case of severe disease. [20] . The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s13340-021-00515-4. Author contributions FB and GA contributed to the acquisition, analysis and interpretation of data and drafted the present work. EL and HM contributed to the conception or design of the present work and critically revised the manuscript. All authors approved the version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of it are appropriately investigated and resolved. The authors received no financial support for the research, authorship, and/or publication of this article. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review Metaanalysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodiumglucose co-transporter-2 inhibitors; implications for COVID19 pandemic Sotagliflozin in patients with diabetes and recent worsening heart failure Dapagliflozin in patients with chronic kidney disease Dapagliflozin in patients with heart failure and reduced ejection fraction Canagliflozin and cardiovascular and renal events in type 2 diabetes Cardiovascular and renal outcomes with empagliflozin in heart failure Canagliflozin and renal outcomes in type 2 diabetes and nephropathy Dapagliflozin and cardiovascular outcomes in type 2 diabetes Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: design and rationale for the DARE-19 study Forest plot of pneumonia risk. SGLTi sodium-glucose cotransporter inhibitors, CI confidence interval Sodium-glucose cotransporter inhibitors may reduce the risk of pneumonia: an updated… SGLT2 inhibition during the COVID-19 epidemic: friend or foe? Regulation of SGLT expression and localization through Epac/PKA-dependent caveolin-1 and F-actin activation in renal proximal tubule cells Statins and PCSK9 inhibitors: what is their role in coronavirus disease 2019? Med Hypotheses Could dapagliflozin attenuate COVID-19 progression in high-risk patients with or without diabetes? Behind DARE-19 concept. J Cardiovasc Pharmacol Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: a population-based retrospective cohort study Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): a structured summary of a study protocol for a randomized controlled trial COVID-19 infection may cause ketosis and ketoacidosis The authors declare that they have no conflict of interest. The present work is a metaanalysis including already published results from RCTs. [3] [4] [5] [6] [7] [8] [9] [10]